Clinical Trial Update: Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating Claudin 18.2-targeted CAR-T cells in unresectable/locally advanced or metastatic gastric, gastroesophageal junction, esophagea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer
• Gastroesophageal Junction Cancer
• Pancreatic Cancer

Drugs mentioned

• Claudin 18.2-targeted CAR-T cells

Snippet

Sponsor: Legend Biotech USA Inc | Conditions: Gastric Cancer, Gastroesophageal-junction Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING